MaaT Pharma and Accinov sign a partnership agreement for the manufacture of investigational medicinal products

MaaT Pharma and Accinov sign a partnership agreement for the manufacture of investigational medicinal products.

MaaT Pharma and Accinov have announced the signing of a partnership agreement for the creation of a GMP platform for the production of clinical batches for an investigational new drug to cure dysbiosis (imbalance of exchanges between the intestinal microbiome and the host) through autologous micro-biotherapy, a solution which is currently totally unique.

Accinov, the biomanufacturing centre which is part of the Lyonbiopôle biocluster, proposes services and hosting for biotech and pharmaceutical companies for the development of experimental products in compliance with GMP standards. Within this partnership, Accinov will take charge of the manufacturing of clinical batches of MaaT Pharma drug candidates in collaboration with its production and quality control teams, thus benefiting from a wide range of expertise and know-how concerning products and production processes.

MaaT Pharma has been hosted by Accinov in their premises since its creation at the beginning of 2015, and the two teams have been working together to implement GMP manufacturing activities within the biomanufacturing centre.

The autologous micro-biotherapy solution developed by MaaT Pharma will provide a safe, standardised treatment for hospital patients’ dysbiosis. These imbalances in the intestinal microbiome, subsequent to certain major treatments, are notably known to result in the appearance of opportunistic infections or bacteria that are multi-resistant to antibiotics.

Furthermore, they are the most frequent cause of diarrhoea following hospitalisation.

The manufacturing platform installed by Accinov manages the whole range of activities connected to the investigational drug. All different stages are mapped out, and particular care is devoted to safety measures. The objective is to guarantee both the confidential nature and the total quality of individual patient medication.
At the end of 2015, Accinov obtained regulatory approval from the French authority ANSM for manufacture of the MaaT Pharma experimental drugs at its site. Using Accinov’s « plug & play ».

MaaT Pharma was able to accelerate development of a GMP manufacturing solution in a record time.

« We are delighted to rely on Accinov for the manufacture of our drug, and consequently benefit from their teams’ know-how in relation to quality and regulatory issues. Our 2 teams worked hand in hand on the project, reporting to Carole Schwintner – Director of Pharmaceutical Development for MaaT Pharma – from the design of the manufacturing unit right through to process implementation – with great professionalism and real agility »,

explained Hervé Affagard, CEO of MaaT Pharma, who has just announced Series A fund-raising for 10 million euro.

« Thanks to Accinov’s new model of GMP biomanufacturing, we can offer SME’s working in bio-technologies and developing innovative therapies a concrete, tailored production solution. Accinov is thus proud to contribute to the dynamics and development of MaaT Pharma, by providing all the quality and pharmaceutical guarantees essential to the manufacturing of clinical batches during the year 2016 ».

concluded Stéphanie Colloud, Accinov’s CEO.